Global Amlodipine Besylate Market Size, Share, and COVID-19 Impact Analysis, By Product Type (Tablets, Capsules, and Others), By Application (Hypertension, Angina, Coronary Artery Disease, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 - 2035

Global Amlodipine Besylate Market Size Insights Forecasts to 2035

• The Global Amlodipine Besylate Market Size Was Estimated at USD 1.61 Billion in 2024
• The Market Size is Expected to Grow at a CAGR of around 7.12% from 2025 to 2035
• The Worldwide Amlodipine Besylate Market Size is Expected to Reach USD 3.43 Billion by 2035
• Asia Pacific is expected to Grow the fastest during the forecast period.

According to a Research Report Published by Spherical Insights and Consulting, The Global Amlodipine Besylate Market Size was worth around USD 1.61 Billion in 2024 and is predicted to Grow to around USD 3.43 Billion by 2035 with a compound annual growth rate (CAGR) of 7.12% from 2025 to 2035. The amlodipine besylate market is growing due to the rising prevalence of hypertension and cardiovascular diseases, along with an aging global population. The availability and affordability of generic versions have also expanded market access.

Market Overview

The global amlodipine besylate market refers to the industry involved in the production, distribution, and sale of amlodipine besylate, a calcium channel blocker primarily used to treat high blood pressure (hypertension) and chest pain (angina). It works by relaxing blood vessels, allowing blood to flow more easily, thereby reducing cardiovascular risks. Amlodipine besylate is widely prescribed worldwide due to its efficacy, affordability, and tolerability, especially in long-term hypertension management. The market is driven by the rising global prevalence of hypertension and cardiovascular diseases, largely due to aging populations, sedentary lifestyles, and poor dietary habits. Increasing awareness of cardiovascular health and improved access to healthcare in emerging economies also contribute to market growth. Generic drug availability, due to patent expirations, has further expanded market accessibility.

Opportunities lie in expanding into rural healthcare markets and developing nations, where untreated hypertension remains prevalent. Innovation in this market includes fixed-dose combinations of amlodipine with other antihypertensive drugs such as valsartan or atorvastatin, improving patient compliance and therapeutic outcomes. Major pharmaceutical players such as Pfizer, Teva Pharmaceuticals, Mylan (Viatris), and Cipla continue to support market growth through production scalability and global distribution networks. Government efforts to support affordable hypertension drugs amlodipine besylate’s adoption as frontline treatment. On September 23, 2025, the National Pharmaceutical Pricing Authority (NPPA) set the retail price of Amlodipine Besylate IP equivalent to Amlodipine 5mg + Valsartan IP 80mg at Rs. 7.41 per tablet. This applies to Windlas Biotech Limited (manufacturer) and Alembic Pharmaceutical Ltd. (marketer), ensuring cost-effective access to this essential hypertension medication.

Report Coverage

This research report categorizes the amlodipine besylate market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the amlodipine besylate market. Recent market developments and competitive strategies such as expansion, type launch, development, partnership, merger, and acquisition, have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the amlodipine besylate market. 

Driving Factors

The primary driving factor for the global amlodipine besylate market is the growing burden of hypertension and related cardiovascular conditions worldwide. As populations age and sedentary lifestyles increase, demand for effective, long-term blood pressure management rises. Amlodipine besylate’s proven efficacy, affordability, and availability as a generic medication make it a preferred choice. Its inclusion in treatment guidelines and essential medicine lists further supports widespread use, particularly in developing and emerging healthcare markets.

Restraining Factors

A key restraining factor in the global amlodipine besylate market is the potential for side effects and patient non-compliance, along with the presence of alternative antihypertensive drugs that may limit its widespread preference and usage.

Market Segmentation

The amlodipine besylate market share is classified into product type, application, and distribution channel.  

• The tablets segment dominated the market in 2024, approximately 82% and is projected to grow at a substantial CAGR during the forecast period.

Based on the product type, the amlodipine besylate market is divided into tablets, capsules, and others. Among these, the tablets segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period. The tablets segment dominated due to their convenience, cost-effectiveness, and widespread acceptance for treating hypertension and cardiovascular diseases. Additionally, advancements in tablet formulations, such as sustained-release and combination therapies, enhance patient adherence and therapeutic outcomes, driving increased demand throughout the forecast period.

• The hypertension segment accounted for the largest share in 2024, approximately 77% and is anticipated to grow at a significant CAGR during the forecast period.

Based on the application, the amlodipine besylate market is divided into hypertension, angina, coronary artery disease, and others. Among these, the hypertension segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. Hypertension is the largest application segment in the amlodipine besylate market due to its global prevalence. Amlodipine besylate is widely prescribed for its effectiveness and low side effect profile. As awareness and diagnosis of this silent killer increase, so does the demand for reliable antihypertensive treatments, driving continued growth in this segment.

• The retail pharmacies segment accounted for the highest market revenue in 2024, approximately 55% and is anticipated to grow at a significant CAGR during the forecast period.

Based on the distribution channel, the amlodipine besylate market is divided into hospital pharmacies, retail pharmacies, online pharmacies, and others. Among these, the retail pharmacies segment accounted for the highest market revenue in 2024 and is anticipated to grow at a significant CAGR during the forecast period. Retail pharmacies offer convenient access to medications for outpatients and those with chronic conditions such as hypertension. Their widespread availability and ease of access support continued market dominance. The expansion of retail pharmacy chains into rural and underserved regions further drives growth, enhancing accessibility and ensuring consistent medication management for a larger patient population.

Regional Segment Analysis of the Amlodipine Besylate Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the amlodipine besylate market over the predicted timeframe.

North America is anticipated to hold the largest share of the amlodipine besylate market over the predicted timeframe. North America holds approximately 38% of the market share of the amlodipine besylate market, primarily due to the high prevalence of cardiovascular diseases, well-developed healthcare infrastructure, and substantial healthcare spending. The United States significantly contributes to this growth, with a large number of patients suffering from hypertension and related conditions. Additionally, the presence of major pharmaceutical companies and the availability of advanced drug formulations support market expansion. These factors collectively strengthen North America’s position as a key player in the global amlodipine besylate market.

Asia Pacific is expected to grow at a rapid CAGR in the amlodipine besylate market during the forecast period. Asia Pacific is rapidly growing in the amlodipine besylate market during the forecast period, with an approximate market share of around 23%, due to the region facing rising prevalence of hypertension and cardiovascular diseases, particularly in countries such as China and India. Increasing healthcare expenditure and improving healthcare infrastructure also contribute to market growth. Additionally, the large and aging population in these countries creates a substantial patient base. Growing awareness about cardiovascular health and better access to pharmaceutical products in emerging markets further drive the region’s expansion in this market.

Europe’s amlodipine besylate market growth is driven by the high prevalence of cardiovascular diseases, particularly in Germany, the UK, and France. Advanced healthcare infrastructure and increasing healthcare spending support treatment access. Growing awareness of hypertension management and government initiatives also contribute. The presence of major pharmaceutical companies offering innovative formulations further boosts the market. Additionally, Europe’s aging population expands the patient base, fueling steady market growth in the region.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the amlodipine besylate market, along with a comparative evaluation primarily based on their type of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes type development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• Dr. Reddy's Laboratories Ltd.
• Sandoz International GmbH
• Cipla Ltd.
• Sun Pharmaceutical Industries Ltd.
• Lupin Limited
• Pfizer Inc.
• Amneal Pharmaceuticals, Inc.
• Apotex Inc.
• Zydus Pharmaceuticals (USA) Inc.
• Alembic Pharmaceuticals Ltd.
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs) 

Recent Development

• In May 2025, Alembic Pharmaceuticals received final USFDA approval for its ANDA for Amlodipine and Atorvastatin Tablets USP. This combination treats hypertension and high cholesterol. The approved product is therapeutically equivalent to Caduet Tablets, marketed by Pharmacia and Upjohn Co. LLC

• In May 2024, Salubris launched Amlodipine and Allisartan tablets (FoLitan) after receiving NMPA drug registration. This ARB/CCB compound targets adults with poorly controlled hypertension, enhancing Salubris’ chronic disease management and strengthening its innovative hypertension treatment portfolio.

• In October 2024, CINFA launched OLMEDINE HCT in the UAE, combining Olmesartan Medoxomil, Amlodipine Besylate, and Hydrochlorothiazide in multiple dosages. This launch addresses the growing hypertension burden in the Middle East, responding to the UAE Ministry of Health’s recognition of the condition as a major public health issue.

• In April 2024, Mylan Laboratories announced the U.S. District Court extended deadlines for its motion to block FDA approval of competing Amlodipine Besylate ANDAs. The FDA is barred from final regulatory action for one week, per the court’s extension request.

• In March 2018, Dr. Reddy’s Laboratories launched generic Amlodipine Besylate and Atorvastatin Calcium tablets in the US. These tablets, equivalent to Caduet, are used to treat high blood pressure in patients with high cholesterol.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the amlodipine besylate market based on the below-mentioned segments: 

Global Amlodipine Besylate Market, By Product Type

• Tablets
• Capsules
• Others

Global Amlodipine Besylate Market, By Application

• Hypertension
• Angina
• Coronary Artery Disease
• Others

Global Amlodipine Besylate Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Global Amlodipine Besylate Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa